Aeglea BioTherapeutics to Announce Fourth Quarter and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
242
Aeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23

AUSTIN, Texas, March 17, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will report its financial results for the quarter and year ended December 31, 2016 on Thursday, March 23 after the market close, and will host a corporate update conference call and webcast at 4:30pm Eastern Time.

Conference Call & Webcast Details To access the live conference call on Thursday, March 23, 20117 at 4:30 p.m. ET via phone, please dial (888) 503-8175 from the United States or +1 (719) 457-2653 internationally. A replay of the call will be available through April 6, 2017 by dialing (844) 512-2921 from the United States or +1 (412) 317-6671 internationally. The conference call ID is 2242567.

To access the live and archived webcast of the presentation, please visit the Investor Relations section of the Aeglea BioTherapeutics website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.

About Aeglea BioTherapeutics Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine. For more information, please visit http://aegleabio.com .

Contact: Media Contact: Kelly Boothe, Ph.D. Pure Communications 415.946.1076 media@aegleabio.com Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics investors@aegleabio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ImmunoGenesis Showcases STING Agonist Progress at SITC

Updated Category News Views 113

STING Agonists: The Next Frontier in Glioblastoma Treatment? Out there in the weeds of immunotherapy, ImmunoGenesis is gearing up for its moment at the SITC 2026 Annual Meeting with its STING agonist, IMGS-203. The stakes are skyscraper-high as this novel treatment makes a play against recurrent glioblastoma (GBM)—one tough cookie in the realm of brain cancers....

Continue Reading
PeptideWorld Paves the Way for Innovative Peptide Education

Updated Category News Views 27

The Rise of Peptide Education Imagine you're wading through a bog of health trends. That's how it feels trying to get a grip on peptide therapies these days, right? Luckily, PeptideWorld, powered by e?vita Health, is here to toss you a lifeline. They're transforming the landscape with a mission to ditch the marketing mumbo-jumbo for hard science. Their pitch?...

Continue Reading
FIS Slashes Forecast: Guidance Under Scrutiny Now

Updated Category News Views 28

Rough Waves for FIS Shareholders If there’s one thing I've learned chewing on greasy bacon over the years, it's that nothing rattles a stock like sketchy numbers and shattered investor confidence. Fidelity National Information Services, or FIS, has just yanked the rug out from its own 2026 forecast, cutting adjusted earnings per share (EPS) to a range of $5.82 to $5.89....

Continue Reading
Basildon Build-to-Rent Marks Progress for Starlight

Updated Category News Views 81

Basildon's New Housing Beacon Nears Completion No two construction milestones are the same, and Starlight Investments sure knows how to make theirs count. Reaching the skies with their project 'The Mercantile' in Basildon, the company has announced topping out—a significant phase in their build-to-rent development saga. With the structural peak reached, we're talking...

Continue Reading
Bluevua Triumphs with Three BASA Awards Wins

Updated Category News Views 18

Bluevua Sweeps the 2026 BASA Awards Stacking accolades like old trading wins, Bluevua just clinched not one, not two, but three 2026 Best of America Small Business Awards (BASA Awards®). If that's not a feather in their cap, I don't know what is. For the uninitiated, these BASA nods are no small potatoes—they're like the Oscars for small businesses. Bluevua, known for...

Continue Reading
Satisfi Labs Secures Two AI Patents, Boosts Reach

Updated Category News Views 78

Paving the Future with Patents Ah, patents. Like stock dividends for the tech world—they don’t change everything outright but can signal some mighty good things ahead. This time around, it’s Satisfi Labs who are in the spotlight. They’ve bagged not one, but two shiny U.S. patents to bolster what they’re calling Satisfi Forward. Honestly, it sounds like a...

Continue Reading
Omnicom Media: A Titan in Media Management Unveiled

Updated Category News Views 156

Omnicom Media's Latest Triumph Omnicom Media (NYSE: OMC) just snagged the 'Leader' badge in the ruthless world of media management services, according to Forrester's new report. Picture a chess game where every move counts—Omnicom's been playing for years, and they're a grandmaster at this point. This isn't some pat on the back; it's recognition of a powerhouse...

Continue Reading
Young Storytellers Honored: Bridging Cultures Through Journalism

Updated Category News Views 11

Leaders of Tomorrow: Campus News Awards 2026 It's no small feat to look at a room full of young journalists and see the future of how stories will be told. But that's exactly what happened at the Campus News Awards 2026 in Shenzhen. Here, kids from Hong Kong, Macao, Taiwan, and Southeast Asia stood proudly with their certificates, ready to tackle the changing landscape of...

Continue Reading
New Story Appoints Drudge, Celebrates Workplace Recognition

Updated Category News Views 103

A Dual Milestone: Leadership and Recognition In an industry chock-full of buzzwords, New Story’s latest moves cut through the noise. They've just announced Adam Drudge as their new Chief People Officer, and wouldn't you know it, they've snagged their third straight Most Loved Workplace® recognition for 2026. When a special ed company starts making waves like this,...

Continue Reading
Crocs™ Gains C2C Circularity Gold for Classic Clogs

Updated Category News Views 125

Turning Plastic into Gold Well, folks, Crocs isn't just about comfort anymore. They're wrapping their iconic Classic Clog in a shiny new accolade: Cradle to Cradle Certified® Circularity Gold Version 5.0. Imagine that—an award for making something meant to last, designed to be repurposed. They're not just slapping new paint on the same old clogs either. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Arlo's New Floodlight Camera Enhances Security at Home and Beyond

Updated Category News Views 90

Introducing the Arlo Wired Floodlight Camera Arlo Technologies, Inc. (NYSE: ARLO), known for its leading smart home security solutions, has introduced an enhanced Wired Floodlight Camera. This innovative all-in-one DIY security solution builds on the company's successful line of wire-free floodlights, leveraging advanced technology to ensure that your outdoor spaces are...

Continue Reading
Bruce Berkowitz Sells Stake in St. Joe: Insights and Impacts

Updated Category News Views 121

Bruce Berkowitz's Significant Sell-Off of St. Joe Shares Recently, it was reported that BRUCE BERKOWITZ, a notable stakeholder of St. Joe (NYSE: JOE), executed a significant sell-off of his shares. According to a filing with the SEC, Berkowitz sold 71,900 shares at a total value of approximately $4.48 million. Such actions from insiders often draw the attention of...

Continue Reading
Yaamava' Resort & Casino Triumphs Again with Top Awards

Updated Category News Views 268

Yaamava' Resort & Casino Continues to Impress Critics and Guests Year after year, Yaamava' Resort & Casino at San Manuel has made a remarkable mark in the gaming industry, consistently rising to the top of prestigious rankings. Most recently, the resort secured its status once again by being voted the Best Overall Casino Outside of Las Vegas and Best Native American...

Continue Reading
Maro Achieves $4.3 Million Seed Funding for Cybersecurity Innovation

Updated Category News Views 516

Maro Secures Significant Seed Funding to Combat Cybersecurity Risks Maro, an innovative player in cognitive security, has successfully raised $4.3 million from Downing Capital Group. This funding is set to empower companies to better manage human risks associated with cybersecurity, transforming the way organizations deal with elements such as social engineering, insider...

Continue Reading
Transforming Cancer Care: The Rise of B7-H3 Inhibitors

Updated Category News Views 246

Understanding B7-H3 Inhibitors and Their Impact on Cancer Treatment The B7-H3 inhibitors market is rapidly emerging as a transformative force in oncology. The significant increase in investment from pharmaceutical giants alongside a rising number of cancer diagnoses has heightened interest and research in this area. This class of inhibitors aims to target the B7-H3...

Continue Reading